These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 16625820)

  • 1. Dipeptidyl peptidase-IV inhibitors can restore glucose homeostasis in type 2 diabetics via incretin enhancement.
    Mest HJ
    Curr Opin Investig Drugs; 2006 Apr; 7(4):338-43. PubMed ID: 16625820
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dipeptidyl peptidase IV inhibitors: how do they work as new antidiabetic agents?
    McIntosh CH; Demuth HU; Pospisilik JA; Pederson R
    Regul Pept; 2005 Jun; 128(2):159-65. PubMed ID: 15780435
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Applications of dipeptidyl peptidase IV inhibitors in diabetes mellitus.
    McIntosh CH; Demuth HU; Kim SJ; Pospisilik JA; Pederson RA
    Int J Biochem Cell Biol; 2006; 38(5-6):860-72. PubMed ID: 16442340
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incretin mimetics and dipeptidyl peptidase-IV inhibitors: potential new therapies for type 2 diabetes mellitus.
    Triplitt C; Wright A; Chiquette E
    Pharmacotherapy; 2006 Mar; 26(3):360-74. PubMed ID: 16503716
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incretins and other peptides in the treatment of diabetes.
    Todd JF; Bloom SR
    Diabet Med; 2007 Mar; 24(3):223-32. PubMed ID: 17263764
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incretin-based therapies: mimetics versus protease inhibitors.
    Brubaker PL
    Trends Endocrinol Metab; 2007 Aug; 18(6):240-5. PubMed ID: 17629492
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparison of the cellular and biological properties of DPP-IV-resistant N-glucitol analogues of glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide.
    Green BD; Gault VA; O'Harte FP; Flatt PR
    Diabetes Obes Metab; 2005 Sep; 7(5):595-604. PubMed ID: 16050953
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dipeptidyl peptidase IV inhibitors: a promising new therapeutic approach for the management of type 2 diabetes.
    Deacon CF; Holst JJ
    Int J Biochem Cell Biol; 2006; 38(5-6):831-44. PubMed ID: 16242377
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dipeptidyl peptidase IV inhibitors and the incretin system in type 2 diabetes mellitus.
    Langley AK; Suffoletta TJ; Jennings HR
    Pharmacotherapy; 2007 Aug; 27(8):1163-80. PubMed ID: 17655515
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of the incretin pathway in the pathogenesis of type 2 diabetes mellitus.
    Freeman JS
    Cleve Clin J Med; 2009 Dec; 76 Suppl 5():S12-9. PubMed ID: 19952298
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dipeptidyl peptidase-IV inhibitors: a major new class of oral antidiabetic drug.
    Idris I; Donnelly R
    Diabetes Obes Metab; 2007 Mar; 9(2):153-65. PubMed ID: 17300591
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rationale for dipeptidyl peptidase 4 inhibitors: a new class of oral agents for the treatment of type 2 diabetes mellitus.
    Campbell RK
    Ann Pharmacother; 2007 Jan; 41(1):51-60. PubMed ID: 17190843
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incretin mimetics and DPP-IV inhibitors for the treatment of type 2 diabetes.
    Nielsen LL
    Drug Discov Today; 2005 May; 10(10):703-10. PubMed ID: 15896683
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Analogs of glucagon-like peptide-1 (GLP-1): an old concept as a new treatment of patients with diabetes mellitus type 2].
    Diamant M; Bunck MC; Heine RJ
    Ned Tijdschr Geneeskd; 2004 Sep; 148(39):1912-7. PubMed ID: 15495988
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incretin-based therapy and type 2 diabetes.
    Hare KJ; Knop FK
    Vitam Horm; 2010; 84():389-413. PubMed ID: 21094909
    [TBL] [Abstract][Full Text] [Related]  

  • 16. From the bench to the bedside: dipeptidyl peptidase IV inhibitors, a new class of oral antihyperglycemic agents.
    Pei Z
    Curr Opin Drug Discov Devel; 2008 Jul; 11(4):512-32. PubMed ID: 18600568
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibitor selectivity in the clinical application of dipeptidyl peptidase-4 inhibition.
    Kirby M; Yu DM; O'Connor S; Gorrell MD
    Clin Sci (Lond); 2009 Sep; 118(1):31-41. PubMed ID: 19780719
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enteroinsular axis of db/db mice and efficacy of dipeptidyl peptidase IV inhibition.
    Nagakura T; Yasuda N; Yamazaki K; Ikuta H; Tanaka I
    Metabolism; 2003 Jan; 52(1):81-6. PubMed ID: 12524666
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the subchronic antidiabetic effects of DPP IV-resistant GIP and GLP-1 analogues in obese diabetic (ob/ob) mice.
    Irwin N; McClean PL; Flatt PR
    J Pept Sci; 2007 Jun; 13(6):400-5. PubMed ID: 17486662
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapies for the treatment of type 2 diabetes mellitus based on incretin action.
    Gallwitz B
    Minerva Endocrinol; 2006 Jun; 31(2):133-47. PubMed ID: 16682937
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.